Shares of Progressive fell 1.06% in premarket trading following the approval of Sanofi's Sarclisa in China. Exelixis experienced a 2.36% decline in premarket trading after issuing its 2025 revenue guidance. In contrast, Dexcom reported preliminary fourth-quarter 2024 revenue of $1.113 billion, marking an 8% increase year-over-year and surpassing the consensus estimate of $1.1 billion. For the full year 2024, Dexcom's revenue reached $4.032 billion, reflecting an 11% year-over-year growth, which aligned with consensus expectations. The company updated its 2024 gross margin guidance to 62% due to non-cash charges related to damaged inventory and production issues. Looking ahead, Dexcom anticipates a 14% revenue growth in 2025, with expectations of increased operating margins as gross margins contribute positively to the bottom line. The company highlighted the ongoing challenges of diabetes management, noting that the incidence of diabetes is projected to increase by 30%.